MAM
ENTA icon

Meeder Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Meeder Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,025
Closed -$25.6K – 974
2026
Q1 		$25.6K Hold
2,025
– – ﹤0.01% 529
2025
Q4 		$31.9K Buy
+2,025
New +$25.7K ﹤0.01% 465
2022
Q4 		– Sell
-90
Closed -$5K – 1150
2022
Q3 		$5K Sell
90
-21
-19% -$1.23K ﹤0.01% 1552
2022
Q2 		$5K Sell
111
-22
-17% -$1.19K ﹤0.01% 1637
2022
Q1 		$9K Buy
+133
New +$8.65K ﹤0.01% 1576
2021
Q4 		– Sell
-106
Closed -$6K – 1523
2021
Q3 		$6K Buy
106
+11
+12% +$544 ﹤0.01% 1852
2021
Q2 		$4K Sell
95
-40
-30% -$1.96K ﹤0.01% 2009
2021
Q1 		$7K Sell
135
-9
-6% -$449 ﹤0.01% 1731
2020
Q4 		$6K Buy
144
+6
+4% +$264 ﹤0.01% 1140
2020
Q3 		$6K Buy
138
+108
+360% +$5.23K ﹤0.01% 1510
2020
Q2 		$2K Buy
+30
New +$1.55K ﹤0.01% 1757
2020
Q1 		– Sell
-127
Closed -$8K – 2370
2019
Q4 		$8K Sell
127
-223
-64% -$13.8K ﹤0.01% 1620
2019
Q3 		$21K Sell
350
-4,008
-92% -$298K ﹤0.01% 1289
2019
Q2 		$368K Buy
4,358
+3,140
+258% +$282K 0.03% 461
2019
Q1 		$117K Sell
1,218
-537
-31% -$48.2K 0.01% 658
2018
Q4 		$124K Sell
1,755
-102
-5% -$7.82K 0.01% 588
2018
Q3 		$159K Sell
1,857
-460
-20% -$46.1K 0.01% 536
2018
Q2 		$269K Buy
2,317
+1,280
+123% +$128K 0.02% 460
2018
Q1 		$85K Sell
1,037
-87
-8% -$6.7K 0.01% 579
2017
Q4 		$66K Buy
1,124
+174
+18% +$8.71K 0.01% 631
2017
Q3 		$45K Buy
950
+795
+513% +$32K ﹤0.01% 699
2017
Q2 		$6K Buy
155
+86
+125% +$2.75K ﹤0.01% 1139
2017
Q1 		$2K Buy
+69
New +$2.15K ﹤0.01% 1361

Other funds holding ENTA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KAM
Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Meeder Asset Management's ENTA Position: Q2 2026 in Review

Meeder Asset Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2026, closing a stake of 2,025 shares — an estimated $25.6K sold.

Meeder Asset Management first reported a position in ENTA in Q1 2017 and held it in 23 quarters. The position peaked at $368K in Q2 2019. 123 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

  • Meeder Asset Management reported no remaining Enanta Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Meeder Asset Management sold 2,025 Enanta Pharmaceuticals shares in Q2 2026, an estimated $25.6K.
  • Meeder Asset Management first reported a position in Enanta Pharmaceuticals in Q1 2017 and held it in 23 quarters.
  • Meeder Asset Management's Enanta Pharmaceuticals position peaked at $368K in Q2 2019.
  • 123 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Meeder Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.